Applying a GAN-based classifier to improve transcriptome-based prognostication in breast cancer
Fig 4
The T-GAN-D outperforms classical biomarkers after merging the MB and TCGA cohorts and significantly stratifies early stage MB patients.
(A) Comparison of the hazard ratios (Cox model, univariate) of a multi-transcript signature (ROR-P) and established prognostic biomarkers (ER, HER2, PR) vs. the CNN and the T-GAN-D before and after cohort merging. (B) Multivariate Cox hazard ratio of the T-GAN-D compared to ROR-P and receptor status and (C) disease stage. (D) Kaplan -Meier curves of Stage I and (E) Stage II patients stratified by the T-GAN-D into low and high risk categories.